FDA, parkinson's disease and BrainSense

Adaptive Deep Brain Stimulation Technology Receives FDA Approval for Parkinson Disease
The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of Parkinson disease.
FDA approves Medtronic’s adaptive technology for Parkinson’s
The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available nationwide in the next few months.
FDA approves first adaptive deep brain stimulation system for Parkinson’s disease
The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in real time based on the patient’s brain activity, according to the manufacturer.
In Parkinson’s fight, Medtronic’s first-in-the-world adaptive therapy feature wins FDA approval
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive technology personalizing treatment of Parkinson’s symptoms using advanced stimulation deep in the brain.
Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's
For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™
Medtronic wins first FDA nod for adaptive DBS for Parkinson’s
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
Medtronic’s BrainSense brain stimulation system approved by FDA for Parkinson’s
Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no
FDA OKs First Adaptive DBS System for Parkinson’s Disease
The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized neuromodulation that responds to the patient’s changing needs.
Medtronic gains FDA OK for self-adjusting DBS system for Parkinson’s
Medtronic received Food and Drug Administration approval for the BrainSense Adaptive deep brain stimulation (DBS) device for people with Parkinson’s disease, a movement disorder of the nervous system.
FDA Approves Medtronic’s BrainSense Adaptive Deep Brain Stimulation for Parkinson Disease
The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real-time brain activity to improve Parkinson disease symptom control without manual adjustments.
Parkinson’s Patients Now Have a New Way to Manage Symptoms
There is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain ...
FDA Approves Medtronic's Adaptive Deep Brain Stimulation System For Parkinson's Patients
BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s ...